FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Petrucci Gary M 		2. Issuer Name and Ticker or Trading Symbol

CARDIOVASCULAR SYSTEMS INC [ NONE ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

651 CAMPUS DRIVE 		3. Date of Earliest Transaction (MM/DD/YYYY)

2/25/2009
(Street)

ST. PAUL, MN 55112
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   2/25/2009     C    36314   A   (1) 359639   D  
 
Common Stock   2/25/2009     D    359639   D   (2) 0   D  
 
Common Stock   2/25/2009     D    50000   D   (2) 0   I   By Partnership   (3)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)     (4) 2/25/2009     D        20000      (4)   (4) Common Stock   20000   $0   0   D  
 
Stock Option (right to buy)     (4) 2/25/2009     D        15000      (4)   (4) Common Stock   15000   $0   0   D  
 
Stock Option (right to buy)     (4) 2/25/2009     D        30000      (4)   (4) Common Stock   30000   $0   0   D  
 
Stock Option (right to buy)     (4) 2/25/2009     D        6680      (4)   (4) Common Stock   6680   $0   0   D  
 
Stock Option (right to buy)     (4) 2/25/2009     D        38320      (4)   (4) Common Stock   38320   $0   0   D  
 
Stock Option (right to buy)     (4) 2/25/2009     D        366161      (4)   (4) Common Stock   366161   $0   0   D  
 
Series A Conv Preferred Stock     (1) 2/25/2009     C        36314      (5)   (5) Common Stock   36314   $0   0   D  
 
Warrant     (6) 2/25/2009     D        20000      (6)   (6) Common Stock   20000   $0   0   D  
 
Warrant     (7) 2/25/2009     C        5157    7/19/2006   7/19/2011   Series A Conv Preferred Stock   5157   $0   0   D  
 
Warrant     (7) 2/25/2009     C     5157       7/19/2006   7/19/2011   Common Stock   5157   $0   5157   D  
 
Warrant     (6) 2/25/2009     D        5157      (6)   (6) Common Stock   5157   $0   0   D  
 
Warrant     (6) 2/25/2009     D        13810      (6)   (6) Common Stock   13810   $0   0   D  
 

Explanation of Responses:
( 1)  Immediately prior to the consummation of the merger between the issuer and Replidyne, Inc., each share of Series A convertible preferred stoick was converted into approximately 1.005 shares of the issuer's common stock.
( 2)  Disposed of pursuant to a merger agreement among the issuer, Responder Merger Sub, Inc. and Replidyne, Inc. (now known as "Cardiovascular Systems, Inc."), pursuant to which each share of the issuer's common stock was converted into 0.647 shares of common stock of Replidyne, Inc.
( 3)  Shares held by Applecrest Partners LTD Partnership, of which Mr. Petrucci is the General Partner.
( 4)  Disposed of pursuant to a merger agreement among the issuer, Responder Merger Sub, Inc. and Replidyne, Inc. (now known as "Cardiovascular Systems, Inc."), pursuant to which each of the issuer's stock options was assumed by Replidyne, Inc. and became exercisable to purchase shares of Replidyne, Inc. common stock; each share covered by the issuer's options was converted into 0.647 shares of common stock of Replidyne, Inc., and the exercise price of each option was adjusted by dividing the pre-merger exercise price by 0.647 and rounding up to the nearest cent.
( 5)  Each share of Series A convertible preferred stock was convertible at any time, at the holder's election, into 1.005 shares of common stock and had no expiration date.
( 6)  Disposed of pursuant to a merger agreement among the issuer, Responder Merger Sub, Inc. and Replidyne, Inc. (now known as "Cardiovascular Systems, Inc."), pursuant to which each of the issuer's common stock warrants was assumed by Replidyne, Inc. and became exercisable to purchase shares of Replidyne, Inc. common stock; each share covered by the issuer's common stock warrants was converted into 0.647 shares of common stock of Replidyne, Inc., and the exercise price of each warrant was adjusted by dividing the pre-merger exercise price by 0.647 and rounding up to the nearest cent.
( 7)  Immediately prior to the consummation of the merger between the issuer and Replidyne, Inc., each Series A convertible preferred stock warrant was converted into a warrant to purchase the issuer's common stock; each Series A convertible preferred share covered by the warrants was converted into approximately 1.005 shares of the issuer's common stock and the exercise price of each warrant was adjusted by multiplying the number of Series A shares covered by the warrant by the warrant exercise price, and dividing by the total number of the issuer's common shares subject to the converted Series A warrant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Petrucci Gary M
651 CAMPUS DRIVE
ST. PAUL, MN 55112 		X



Signatures
/s/ Carlye S. Landin as Attorney-in-Fact for Gary M. Petrucci pursuant to Power of Attorney previously filed. 2/27/2009
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Cardiovascular Systems Charts.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Cardiovascular Systems Charts.